In BRCA germ-line deficient and platinum sensitive sporadic epithelial ovarian cancers, PARP inhibitor (Niraparib, Olaparib, Rucaparib) maintenance therapy improves progression-free survival (PFS) [1–3]. Here, PARP1 is linked to ovarian carcinoma.